Michael Alan Rosenzweig, M.D., M.S.
As a hematologist and member of the plasma cell disease team, Dr. Rosenzweig has a clinical focus on multiple myeloma and related diseases, including Waldenstrom macroglobulinemia, POEMs syndrome and light chain amyloidosis.
Dr. Rosenzweig enjoys caring for a multitude of patients with multiple myeloma at all stages of the disease process and actively participates in clinical research exploring new treatments. He has a particular interest in smoldering myeloma, a precursor condition to active disease, and is actively involved in research exploring new treatments to prevent disease progression.
As the director of the amyloidosis program at City of Hope, he greatly enjoys caring for patients with all forms of amyloidosis, including light chain (AL), a disease closely related to multiple myeloma, as well as transthyretin (TTR), secondary amyloidosis (AA) and LECT2.
He works closely with a multidisciplinary team, including cardiology, nephrology and neurology, to care for patients with amyloidosis. His research interests include finding new treatments for amyloidosis at various stages of the disease process.
1997-2001, M.D., University of Arizona College of Medicine, Tucson, AZ
1993-1994, M.S., Physiology and Biophysics
1989-1993, B.A., Psychology, Emory University, Atlanta, GA
2009-2011, Fellow, Bone Marrow Transplantation, Memorial Sloan-Kettering Cancer Center New York, NY
2006-2009, Fellow, Hematology/Oncology, Boston Medical Center, Boston, MA
2001-2004, Categorical Resident in Internal Medicine and Temporary Ambulatory Care Chief Resident, Boston Medical Center, Boston, MA
2020-present, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2011-2020, Assistant Professor and Staff Physician, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2004-2006, Clinical Instructor in Medicine, Amyloid Treatment and Research Program, Boston University, Boston, MA
2020, Pfizer Inc. Optimization of the identification, diagnostic evaluation and management of patients with transthyretin amyloidosis. Co-principal investigator with Dr. Faizi Jamal, M.D., Cardiology
2018, Steven Gordon and Briskin Family Innovation Grant Recipient
2015, Recipient of the David Seldin Memorial Research Grant: Amyloidosis Foundation
2013, ASBMT: Clinical Research Training Course Scholar
2008, Boston Medical Center Fellowship in Hematology/ Oncology: Chief Fellow
2001, University of Arizona College of Medicine Graduation Class Speaker
American Society of Hematology
American Society for Clinical Oncologists
International Society of Amyloidosis
- Rosenzweig M, Palmer J, Tsai NC, Synold T, Wu X, Tao S, Hammond SN, Buettner R, Duarte L, Htut M, Karanes C, Nathwani N, Pichiorri F, Sahebi F, Sanchez JF, Chowdhury A, Krishnan A, Forman SJ, Rosen ST Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 trial .Leuk Lymphoma. 2020 Apr 8:1-9
- Palladini G, Kastritis E, Maurer MS, Zonder JA, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics TJ, Rosenzweig MA, Sanchorawala V, Qin X, Vasey SY, Weiss B, Vermeulen J, Merlini G, Comenzo RL. Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. Blood April 3, 2020. Epub ahead of print.
- Buettner R, Morales C, Caserta E, Troadec E, Gunes EG, Viola D, Khalife J, Li H, Keats JJ, Christofferson A, Wu X, Synold TW, Palmer J, Sanchez JF, Pozhitkov A, Vaidehi N, Marcucci G, Krishnan A, Rosenzweig M, Pichiorri F, Rosen ST. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv. 2019 Apr 9;3(7):1027-1032
- Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018 July 23; 7 (10)
- Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2018 Jul;32(7):1567-1574
- Oregel K, Shouse GP, Oster C, Martinez F, Wang J, Rosenzweig M, Deisch JK, Chen CS, Nagaraj G. Atypical PResentaiton of Gelsolin Amyloidosis in a Man of African Descent with a Novel Mutation in the Gelsolin Gene. American Journal Case Report. 2018 March 30;19:374-381.
- Rosenzweig M, Urak R, Walter M, Lim L, Sanchez JF, Krishnan A, Forman S, Wang X. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. Cytotherapy. 2017 Jul;19(7):861-866.
- Rosenzweig M, Krishnan A. Treatment of Multiple Myeloma: Finding the Right Combination. Oncology (Williston Park) 2016 May; 30(5): 466-7
- Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015
- Pastores M, Rosenzweig M, Jakubowski A. Principles of Critical Care: Hematopoeietic Stem Cell Transplantation and Graft-Versus-Host Disease. 4th ed. McGraw-Hill Education. 2015. Print.